Wound healing and diabetes mellitus (Q35085211)

6 August 2017

1 reference

title

Wound healing and diabetes mellitus (English)

1 reference

6 August 2017

1 reference

David G Greenhalgh

1

1 reference

6 August 2017

1 January 2003

1 reference

Clinics in plastic surgery

6 August 2017

1 reference

6 August 2017

30

1 reference

6 August 2017

1

1 reference

6 August 2017

37-45

1 reference

Antibiotic selection for diabetic foot infections: a review

6 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0094-1298%2802%2900066-4

7 January 2021

Assessment and management of foot disease in patients with diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0094-1298%2802%2900066-4

7 January 2021

PDGF and TGF-alpha act synergistically to improve wound healing in the genetically diabetic mouse.

1 reference

https://api.crossref.org/works/10.1016%2FS0094-1298%2802%2900066-4

7 January 2021

Synergistic actions of platelet-derived growth factor and the insulin-like growth factors in vivo.

1 reference

https://api.crossref.org/works/10.1016%2FS0094-1298%2802%2900066-4

7 January 2021

The role of growth factors in wound healing

1 reference

https://api.crossref.org/works/10.1016%2FS0094-1298%2802%2900066-4

7 January 2021

Regulation of vascular endothelial growth factor expression in cultured keratinocytes. Implications for normal and impaired wound healing

1 reference

https://api.crossref.org/works/10.1016%2FS0094-1298%2802%2900066-4

7 January 2021

Induction of keratinocyte growth factor expression is reduced and delayed during wound healing in the genetically diabetic mouse

1 reference

https://api.crossref.org/works/10.1016%2FS0094-1298%2802%2900066-4

7 January 2021

Analysis of the acute and chronic wound environments: the role of proteases and their inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0094-1298%2802%2900066-4

7 January 2021

Gelatinase activities in wounds of healing-impaired mice versus wounds of non-healing-impaired mice

1 reference

https://api.crossref.org/works/10.1016%2FS0094-1298%2802%2900066-4

7 January 2021

Sorbitol, phosphoinositides, and sodium-potassium-ATPase in the pathogenesis of diabetic complications

1 reference

https://api.crossref.org/works/10.1016%2FS0094-1298%2802%2900066-4

7 January 2021

Banting lecture 1986. Does a common mechanism induce the diverse complications of diabetes?

1 reference

https://api.crossref.org/works/10.1016%2FS0094-1298%2802%2900066-4

7 January 2021

Activation of protein kinase C by elevation of glucose concentration: proposal for a mechanism in the development of diabetic vascular complications

1 reference

https://api.crossref.org/works/10.1016%2FS0094-1298%2802%2900066-4

7 January 2021

Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications

1 reference

https://api.crossref.org/works/10.1016%2FS0094-1298%2802%2900066-4

7 January 2021

Advanced protein glycosylation induces transendothelial human monocyte chemotaxis and secretion of platelet-derived growth factor: role in vascular disease of diabetes and aging.

1 reference

https://api.crossref.org/works/10.1016%2FS0094-1298%2802%2900066-4

7 January 2021

Cachectin/TNF and IL-1 induced by glucose-modified proteins: role in normal tissue remodeling

1 reference

https://api.crossref.org/works/10.1016%2FS0094-1298%2802%2900066-4

7 January 2021

Evidence for glucose-mediated covalent cross-linking of collagen after glycosylation in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0094-1298%2802%2900066-4

7 January 2021

Aminoguanidine treatment inhibits the development of experimental diabetic retinopathy

1 reference

https://api.crossref.org/works/10.1016%2FS0094-1298%2802%2900066-4

7 January 2021

The effects of ulcer size and site, patient's age, sex and type and duration of diabetes on the outcome of diabetic foot ulcers

1 reference

https://api.crossref.org/works/10.1016%2FS0094-1298%2802%2900066-4

7 January 2021

Prognostic value of the clinical examination of the diabetic foot ulcer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-1298%2802%2900066-4

7 January 2021

Healing of diabetic neuropathic foot ulcers receiving standard treatment. A meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0094-1298%2802%2900066-4

7 January 2021

Risk factors for delayed healing of neuropathic diabetic foot ulcers: a pooled analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS0094-1298%2802%2900066-4

7 January 2021

Management and outcome of severe diabetic foot infections

1 reference

https://api.crossref.org/works/10.1016%2FS0094-1298%2802%2900066-4

7 January 2021

Transcutaneous oxygen tension and toe blood pressure as predictors for outcome of diabetic foot ulcers

1 reference

https://api.crossref.org/works/10.1016%2FS0094-1298%2802%2900066-4

7 January 2021

Off-loading the diabetic foot wound: a randomized clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0094-1298%2802%2900066-4

7 January 2021

Hyperbaric oxygen therapy and the diabetic foot

1 reference

https://api.crossref.org/works/10.1016%2FS0094-1298%2802%2900066-4

7 January 2021

Systemic hyperbaric oxygen therapy: lower-extremity wound healing and the diabetic foot

1 reference

https://api.crossref.org/works/10.1016%2FS0094-1298%2802%2900066-4

7 January 2021

Classification and treatment of chronic nonhealing wounds. Successful treatment with autologous platelet-derived wound healing factors (PDWHF).

1 reference

https://api.crossref.org/works/10.1016%2FS0094-1298%2802%2900066-4

7 January 2021

Effectiveness of platelet releasate for the treatment of diabetic neuropathic foot ulcers

1 reference

https://api.crossref.org/works/10.1016%2FS0094-1298%2802%2900066-4

7 January 2021

The treatment of donor sites with cultured epithelial grafts

1 reference

https://api.crossref.org/works/10.1016%2FS0094-1298%2802%2900066-4

7 January 2021

Multicentre experience in the treatment of burns with autologous and allogenic cultured epithelium, fresh or preserved in a frozen state

1 reference

https://api.crossref.org/works/10.1016%2FS0094-1298%2802%2900066-4

7 January 2021

Three-dimensional fibroblast culture implant for the treatment of diabetic foot ulcers: metabolic activity and therapeutic range

1 reference

https://api.crossref.org/works/10.1016%2FS0094-1298%2802%2900066-4

7 January 2021

Use of dermagraft, a cultured human dermis, to treat diabetic foot ulcers

1 reference

https://api.crossref.org/works/10.1016%2FS0094-1298%2802%2900066-4

7 January 2021

Expression of interleukin-1alpha, interleukin-6, and basic fibroblast growth factor by cultured skin substitutes before and after grafting to full-thickness wounds in athymic mice

1 reference

https://api.crossref.org/works/10.1016%2FS0094-1298%2802%2900066-4

7 January 2021

Graftskin, a human skin equivalent, is effective in the management of noninfected neuropathic diabetic foot ulcers: a prospective randomized multicenter clinical trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0094-1298%2802%2900066-4

7 January 2021

Recombinant human platelet-derived growth factor-BB (becaplermin) for healing chronic lower extremity diabetic ulcers: an open-label clinical evaluation of efficacy.

1 reference

https://api.crossref.org/works/10.1016%2FS0094-1298%2802%2900066-4

7 January 2021

Efficacy and safety of becaplermin (recombinant human platelet-derived growth factor-BB) in patients with nonhealing, lower extremity diabetic ulcers: a combined analysis of four randomized studies

1 reference

https://api.crossref.org/works/10.1016%2FS0094-1298%2802%2900066-4

7 January 2021

Clinical evaluation of recombinant human platelet-derived growth factor for the treatment of lower extremity diabetic ulcers. Diabetic Ulcer Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0094-1298%2802%2900066-4

7 January 2021

Efficacy and safety of a topical gel formulation of recombinant human platelet-derived growth factor-BB (becaplermin) in patients with chronic neuropathic diabetic ulcers. A phase III randomized placebo-controlled double-blind study

1 reference

https://api.crossref.org/works/10.1016%2FS0094-1298%2802%2900066-4

7 January 2021

Clinical protocol: Phase I trial to evaluate the safety of H5.020CMV.PDGF-B for the treatment of a diabetic insensate foot ulcer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-1298%2802%2900066-4

7 January 2021

10.1016/S0094-1298(02)00066-4

Identifiers

DOI

1 reference

6 August 2017

1 reference

PubMed ID

12636214